Conference Coverage
Latest News
‘New dawn’ for aldosterone as drug target in hypertension?
The medication lowered systolic blood pressure significantly more than placebo, with the greatest effects seen in adults with obesity.
Conference Coverage
Low-dose aspirin cuts type 2 diabetes risk in over-65s
“At this time, our findings are exploratory but ignite the debate of the important role that anti-inflammatory approaches may play in preventing...
Conference Coverage
More weight loss linked with more benefit in STEP-HFpEF
“The outcomes we’ve already seen in STEP-HFpEF were largely symptomatic, which are extraordinarily important, but there may be a completely...
Conference Coverage
ESC backs SGLT2 inhibitor plus GLP-1 in diabetes with high CVD risk
Another major change in the new ESC guideline revision is introduction of a CVD risk calculator intended to estimate the risk among people with...
Conference Coverage
Wegovy scores HFpEF benefits in people with obesity
The results “indicate that treatment with semaglutide is a valuable therapeutic approach in the management of patients with HFpEF and obesity.”
Conference Coverage
Growth hormone links with worse T2D control in adolescents
Researchers hope to “leverage these data to find predictive markers” that could identify adolescents with type 2 diabetes “at risk for...
Conference Coverage
Studies link GLP-1 agonists to progression of diabetic retinopathy
“The strength of these effects depends on the specific GLP-1 receptor agonist used, patient-specific clinical characteristics, and demographics...
Commentary
Time-restricted eating gains for weight and glycemic control
While no evidence clearly shows that 8 hours is the best eating-window duration, “we think 8 hours is a good sweet-spot for motivated people.”
Conference Coverage
Benefits of bariatric surgery persist for 12 years
The results reinforce the potential role of surgery “as an option to improve diabetes-related outcomes, including people with a BMI of less than...
Conference Coverage
Semaglutide use surges in U.S. adults with type 2 diabetes
“The market share of GLP-1 agonists is likely to expand in patients with type 2 diabetes,” especially those who also have obesity.
Conference Coverage
Intermittent fasting vs. calorie counting for weight loss
“If you’ve tried calorie counting, that’s not working for you or if you’re kind of burnt out, this is something else that you could try.”